Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma - Wikidata - wikimedia - TriplyDB

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

http://www.wikidata.org/entity/Q35915726

about

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies Novel agents in the treatment of multiple myeloma: a review about the future Clinical use and applications of histone deacetylase inhibitors in multiple myeloma The role of epigenetics in kidney malignancies Small molecule inhibitors of zinc-dependent histone deacetylases DangER: protein ovERload. Targeting protein degradation to treat myeloma Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma Autophagy in plasma cell pathophysiology New and emerging HDAC inhibitors for cancer treatment Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Structural insights into HDAC6 tubulin deacetylation and its selective inhibition Novel therapeutic strategies for multiple myeloma Development of a histone deacetylase 6 inhibitor and its biological effects NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Recent advances in antimultiple myeloma drug development.Advances in epigenetic glioblastoma therapy.Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines New strategies in the treatment of multiple myeloma.HDAC6 inhibition restores ciliary expression and decreases tumor growth Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Histone deacetylases and cancer.Misfolded proteins: from little villains to little helpers in the fight against cancer.Tubulin acetylation: responsible enzymes, biological functions and human diseases.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Use of epigenetic drugs in disease: an overview.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells

P2860

Q24309277-82F3B456-C4BB-430B-8EED-6D1B4E7EC92C Q26739689-780BA7DD-4D2C-4C96-B64B-DAF4F155F4D8 Q26745924-B342B3AC-1C10-43C3-95BD-23027E2D338B Q26745930-8E5BEC74-3F6A-44F6-89D1-1451884062D8 Q26801233-2C09D8F5-A46D-408F-A52A-0E05D0DCC8D7 Q26824515-31DE0AD1-A98A-4D72-B4D8-A74B7FCD51B9 Q26825417-02BAB19B-914F-46F6-8A61-06E8ACCBA252 Q26830233-DEDC0396-25F0-44B4-A637-0F8D59605D10 Q26851166-A58C2000-156F-43C7-A5C6-C56CA91AC789 Q27015920-88705D87-2E85-4FEA-801F-CAB091368243 Q27022413-99761A4F-955D-43AE-8F08-AD1772664AF5 Q27026478-51B2A6F7-DF97-4922-814E-D6E180B15DCA Q27721834-D333A7D4-B595-4150-85E2-098D3C5D3A73 Q28081590-AAFE49DD-1578-4312-AE72-E6A57853D779 Q28298272-9497F68A-206C-4E20-BA4E-857526DB5C9E Q28308089-A60536DC-7DB5-481E-B6A4-8B6960E8C95F Q28540241-BC5E5AFB-784E-4B48-8C4D-63001C7C0A42 Q28572123-1EFAF2A8-5257-4C39-A464-C2D9E288585F Q28818731-B4BF2ED4-B9EB-4B76-BF2F-75029193B4E7 Q30144009-21D7EC28-765B-41CF-91AC-EF47C7384AD5 Q30410019-E8A4CBEA-D361-4CB2-B4C4-39D6BF81FC17 Q33414827-B6D4C9E6-0498-4F60-A6A7-C297D2D790AC Q33416297-5970AD85-BF4A-44B4-8F33-F7C66AF1C19D Q33567030-6246AB84-DE9C-47A6-A8F2-641ECF9BDF95 Q33586017-4B05FE1E-DCB2-40D1-AC7D-499265890D15 Q33621610-6F2A33C4-0B59-4BA0-9105-9874C5994187 Q33649853-0439F16F-4009-4C24-8C36-E440D01C8097 Q33750712-2738D409-00B9-43CB-A4BF-289F4EE3079A Q33958520-AF944D6B-053C-4FC4-B0C9-D48CC8826D55 Q34035361-35C56415-F17D-438D-A151-7AA11AD2FA53 Q34194704-3A778664-C6B1-4149-823E-CA38214B43B7 Q34224278-B98B4B07-6BF8-4863-ADA9-95BDA6D48531 Q34298745-2A4E995E-D8C3-4F89-9AEB-1A39F4F9CAB0 Q34466592-A3FDD748-886B-45B3-95BE-C687A692E891 Q34487624-089E2026-ED97-4E61-8217-E818E0319060 Q34602263-6EED708D-7919-4FA5-99DE-B54A5CED9B60 Q34607095-513AFF59-8264-410E-AA43-F419F74A7185 Q34773850-5B98D481-2142-40D6-8EC7-8DB889E05FE0 Q35007061-6EA58EA6-639D-4078-A2B7-9CE3562C26CF Q35213084-6287C2F5-E48B-4E5A-BC72-D5C4A9593FDB

P2860

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

http://www.wikidata.org/entity/Q35915726

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@ast

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@en

type

label

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@ast

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@en

prefLabel

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@ast

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@en

P1433

Q35915726-D0E4E8C3-90A2-438D-AC39-BC9BA7720645

P1476

Q35915726-5432ADE8-D899-494E-B242-6289E600A223

P2093

Q35915726-124C356D-E6A2-47E2-BA45-54604F9F6EE0

Q35915726-290FC602-DC92-4692-BE01-E622BA29A965

Q35915726-2DD5F05C-0070-458B-928B-20ACE343D22C

Q35915726-4A10EE05-4B73-4218-B55E-361C3F4837A1

Q35915726-58FEADDE-3E4E-4488-A870-AB9F585BAAE1

Q35915726-6BDEA405-0F9A-4CB9-A5F5-FC277C35A17C

Q35915726-7E8DA6DC-7C66-4473-8DF5-3202129824E9

Q35915726-863B8EBB-7160-4192-BD56-B3E7B26F88FA

Q35915726-8DD088FD-6460-49BC-9D87-C1ED7696C487

Q35915726-8F6E817B-2C2D-451E-B1B5-5E237F883669

P2860

Q35915726-042E8C8C-7240-4DFA-9715-53E9F67E33CD

Q35915726-06690CA2-A7FE-43E7-9D67-344CB6BA3B98

Q35915726-091DCFE3-26DE-410A-9ADA-219AC57D324E

Q35915726-09CA1A52-81B8-4A5A-9EFB-AB0B6B932ABF

Q35915726-0B15C2A6-4793-4CA2-82AB-8CB39AA8E6F7

Q35915726-17BC43D8-63BD-40DA-9536-0260A72EC518

Q35915726-17FBE27B-2450-4BE1-A05E-8B4BB909B1FB

Q35915726-1EE16B1A-2672-4C86-9114-BB5BC43F013E

Q35915726-2AFC7A05-7286-45C5-976F-5540F4270137

Q35915726-31611A84-311D-4E77-A54A-F62C0016499E

P304

Q35915726-8E85C27A-65C2-4413-A0DB-88CB392CD3FD

P31

Q35915726-16AE23E3-12F9-498B-A712-C9C3C9A998D4

P356

Q35915726-32974738-9BE7-4992-9FF9-561EA09189A5

P407

Q35915726-BAE5A568-860E-45A9-BB8E-7F1033001A41

P433

Q35915726-F5EB95E2-8DB9-4036-A980-046A20AF295E

P478

Q35915726-74FB76FF-7952-424D-AEEA-ABD0F3D7CB85

P50

Q35915726-7BDAC667-B8A0-433A-B56F-1BFD8913E93D

Q35915726-8676969E-8CD2-4857-BEA2-C3B803A4861E

P577

Q35915726-D6B9D071-3682-4443-B6A7-D8BE8C6366A8

P5875

Q35915726-17A86D66-7FBB-4656-95B0-71C25A0B949F

P698

Q35915726-808C3894-3CB9-46D8-AEC0-DF7362DD35A9

P932

Q35915726-4A9C82DE-4B4F-408B-832D-E4F5DC41226D

P356

BLOOD-2011-10-387365

P1433

P1476

Preclinical activity, pharmaco ...... bortezomib in multiple myeloma

@en

P2093

David Tamang

http://www.w3.org/2001/XMLSchema#string

Diana Cirstea

http://www.w3.org/2001/XMLSchema#string

Homare Eda

http://www.w3.org/2001/XMLSchema#string

James Bradner

http://www.w3.org/2001/XMLSchema#string

Jen-Chieh Tseng

http://www.w3.org/2001/XMLSchema#string

John H van Duzer

http://www.w3.org/2001/XMLSchema#string

Loredana Santo

http://www.w3.org/2001/XMLSchema#string

Matthew Jarpe

http://www.w3.org/2001/XMLSchema#string

Min Yang

http://www.w3.org/2001/XMLSchema#string

Miriam Canavese

http://www.w3.org/2001/XMLSchema#string

P2860

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Functions of site-specific histone acetylation and deacetylation

Chemical phylogenetics of histone deacetylases.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

P304

2579-2589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-10-387365

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2012-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221764268

http://www.w3.org/2001/XMLSchema#string

P698

22262760

http://www.w3.org/2001/XMLSchema#string

P932

3337713

http://www.w3.org/2001/XMLSchema#string